Please directly call our main office to complete your appointment
Virtual Consultations
Book Appointment
850-407-2803
Menu
Semaglutide is not directly indicated to increase energy. However, by helping to manage blood sugar, promote weight loss, and reduce appetite, semaglutide may help improve energy levels.
Obesity and being overweight can zap anyone’s energy. The extra weight makes simple physical tasks more difficult and tiring. On top of that, many obesity-related health conditions like sleep apnea, joint pain, and fatigue take a huge toll on your energy levels.
If you feel like you're always dragging yourself through the day, you're not alone. Millions of people struggle with low energy levels due to excess weight.
The good news? Effective weight loss can be a game changer when it comes to boosting your energy. And one of the most effective prescription weight loss drugs available today is semaglutide.
But does semaglutide give you energy directly? Or are its effects on energy more indirect? Keep reading to find out.
Semaglutide is an injectable prescription medication originally approved for treating type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists.
The drug mimics a hormone called glucagon-like peptide-1 (GLP-1) that your body naturally produces. This hormone helps regulate blood sugar levels by stimulating insulin release after you eat. It also suppresses appetite.
Semaglutide helps lower blood sugar in two main ways:
In recent years, semaglutide was also approved by the FDA specifically for chronic weight management.
Clinical trials showed that it helped overweight or obese patients lose significant weight compared to placebo. The way it promotes weight loss is mainly by reducing appetite and calorie intake.
Now let's get into the central question: can semaglutide give you an energy boost like caffeine or other stimulants?
This is a common misunderstanding about semaglutide. Since it leads to weight loss, people often assume it will also provide a direct energy boost.
The fact is, semaglutide is NOT a stimulant and does not directly increase energy.
Unlike caffeine or amphetamines, semaglutide does NOT work by stimulating the central nervous system.
Therefore, it won't give you sudden bursts of energetic focus and motivation like a strong cup of coffee.
Rather, semaglutide promotes weight loss primarily through appetite reduction. This, in turn, decreases overall calorie intake and body weight over weeks and months - leading to INDIRECT effects on energy.
So while semaglutide itself won’t make you feel instantly energetic, losing excess weight over time on semaglutide can absolutely help increase your energy levels.
Though semaglutide doesn’t directly boost energy, substantial weight loss on semaglutide has several indirect effects that can greatly improve energy levels:
One of semaglutide’s main effects is lowering and stabilizing blood sugar levels. This is a huge benefit when it comes to steady, sustained energy levels.
When your blood sugar is frequently spiking up and crashing down throughout the day, your energy goes on a rollercoaster ride too.
Periods of high blood sugar can leave you feeling restless and wired. Then when your blood sugar plummets, you’re left feeling shaky, tired, and sluggish.
By regulating your blood sugar, semaglutide helps avoid these energy fluctuations. This provides your body with a constant stream of fuel to power through your day.
Carrying excess body fat can be exhausting! When you lose weight, everyday activities like walking, exercising, and doing chores become much less tiring.
Just a 10% reduction in body weight can make physical tasks feel significantly easier and improve stamina. With semaglutide, many patients lose 15-20% or more of their initial body weight.
As the pounds come off on semaglutide, energy-draining fat deposits also shrink. This directly reduces feelings of fatigue, heaviness, and sluggishness.
Sleep apnea and other conditions that disrupt sleep are common in overweight people. Poor sleep takes a huge toll on your energy reserves.
With substantial weight loss from semaglutide treatment, patients often report improved sleep quality. 7-9 hours of uninterrupted sleep allows the body to recharge.
So if semaglutide can help you sleep better, you’ll have more energy to take on your days.
Beyond just joint pain and sleep apnea, obesity is linked to several chronic illnesses. These include type 2 diabetes, heart disease, fatty liver disease, and hormonal imbalances.
Symptoms like fatigue, weakness, and low endurance are common with these conditions. However, significant weight loss often leads to major improvement or even remission of some associated health issues.
As your overall health improves with a slimmer body, you’ll likely feel revitalized with more vibrancy and vitality.
Now, it is true that some patients report increased fatigue and tiredness when they first begin taking semaglutide.
There are a few reasons this can happen temporarily:
| Calorie Deficit | Since semaglutide curbs your appetite, you may be consuming fewer calories than your body is used to. This can leave you feeling drained initially until you adapt. |
| Gastrointestinal Side Effects | Semaglutide commonly causes nausea, vomiting, and diarrhea, especially in the first few weeks. Dehydration and nutrient depletion from GI side effects can temporarily zap energy. |
| Body Adjusting | Adapting to major changes in appetite-regulating hormones and blood sugar levels can require an adjustment period as your body regulates. |
For most people, this early tiredness resolves within a few days to weeks as your body acclimates to the drug’s effects. Making sure to drink plenty of fluids, get enough rest, and eat nutrient-dense foods can help overcome initial fatigue.
If lethargy persists, consult your doctor about whether semaglutide is the right treatment for your needs.
While semaglutide doesn’t provide instant, stimulant-like energy, substantial weight loss on this medication can have transformative effects on your fatigue and stamina.
By indirectly improving blood sugar control, reducing obesity-related diseases, enhancing sleep quality, and making physical tasks easier, semaglutide helps eliminate many energy drains.
Just remember, energy benefits emerge gradually as you lose weight over weeks and months. Semaglutide won’t replace your morning coffee as an instant pick-me-up.
Always work closely with your healthcare provider to see if semaglutide is appropriate for your weight loss and wellness goals. With healthy lifestyle changes, this powerful medication can help you finally reclaim your energy and live life to the fullest!
Contact Dr. V Medical Aesthetics today to explore if semaglutide, combined with lifestyle changes, is the right solution to help you lose weight, boost energy, and live life fully.
A New Era of Cardiovascular Protection for Individuals With Overweight or Obesity
The SELECT Trial looked at using semaglutide to lower the risk of major cardiovascular events (MACE) in people with overweight or obesity. The research reveals that semaglutide reduces the risk of heart attacks, strokes, and death from cardiovascular disease.
Obesity is a growing public health crisis affecting millions globally. Excess weight significantly increases the risk of developing multiple health problems, especially cardiovascular disease. Heart attack, stroke, and heart failure are more common in people with obesity. Therefore, strategies to reduce cardiovascular risk in this high-risk population are urgently needed.
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as a promising option for weight management and improvement of cardiometabolic parameters. But what are the actual effects of semaglutide on cardiovascular event rates and outcomes?
The SELECT trial provides pivotal insights.
Semaglutide is an injectable drug that mimics the effects of GLP-1, a hormone released from the gut after meals. It binds to GLP-1 receptors in the pancreas, boosting insulin production while suppressing glucagon secretion. This lowers blood sugar levels.
Semaglutide also acts on GLP-1 receptors in the brain to increase feelings of fullness and reduce appetite. By decreasing calorie intake, semaglutide induces weight loss. The FDA has approved semaglutide for chronic weight management in adults with obesity or overweight.
Obesity is an independent risk factor for cardiovascular disease. It predisposes to atherosclerosis, hypertension, dyslipidemia, and diabetes - key drivers of heart attacks, strokes, and heart failure.
People with obesity have a greater risk of experiencing an adverse cardiovascular event. Heart disease is the leading cause of death in this population. Clearly, obesity is a state of heightened cardiovascular vulnerability requiring risk-reduction strategies.
The cardiovascular benefits of weight loss are well-established. But could semaglutide offer cardiovascular advantages beyond weight reduction alone?
This was the key question behind the SELECT trial.
SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) was an academic-led, placebo-controlled, double-blind trial across 4 continents. It aimed to definitively assess the cardiovascular effects of semaglutide 2.4 mg once-weekly in people with obesity.
With a cohort of over 17,000, it represents the largest trial to date evaluating a weight-loss medication’s cardiovascular impact. Experts hailed SELECT as a long-awaited study addressing a critical clinical and public health question.
Researchers randomly assigned over 17,000 participants to receive either semaglutide or a placebo injection once per week for around 2 years.
The participants included adults who were overweight or had obesity, and had existing heart disease or risk factors for heart disease, but did not have diabetes.
The main goal was to see if semaglutide could reduce the risk of major cardiovascular problems like heart attacks, strokes, and cardiovascular death (known as "MACE").
Researchers also looked at the effect on factors like hospitalization for heart failure, weight loss, and metabolic measures.
Key Findings: Semaglutide Greatly Lowered Cardiovascular Risk
The results, presented in 2021, were very positive.
Compared to placebo, semaglutide lowered the risk of MACE by 20%
This protective effect was seen early and continued throughout the study
Specifically, semaglutide also lowered the risk of:
Beyond that, semaglutide reduced hospitalizations for heart failure and unstable angina.
These impressive improvements occurred along with substantial weight loss. On average, participants lost about 15% of their starting weight.
This weight reduction likely played a role in the cardiovascular benefits. But semaglutide may provide heart protection in other ways too.
While diminished weight and favorable metabolic changes mediate some of semaglutide’s cardiovascular protection, additional mechanisms are likely involved.
In lipolysis experiments, semaglutide exhibited anti-inflammatory effects in human adipose tissue – beneficial for atherosclerosis. Animal studies reveal direct cardioprotective actions such as lessening ischemia-reperfusion injury.
Furthermore, the cardiovascular risk reduction with semaglutide exceeded that anticipated from the degree of weight loss alone. This strongly suggests protective effects beyond just weight change.
Teasing out the weight-independent cardiovascular effects of semaglutide merits further research. But the totality of evidence demonstrates robust cardiovascular advantages.
Based on SELECT, semaglutide provides broad cardiovascular protection in people with overweight/obesity, both with and without established cardiovascular disease.
Some subgroups with very high baseline cardiovascular risk appeared to gain even greater risk reduction with semaglutide. For example, patients with preexisting peripheral artery disease saw a 40% lower risk of MACE.
People with obesity plus the following characteristics may be strong candidates for semaglutide to mitigate cardiovascular risk:
| Established Atherosclerotic Cardiovascular Disease | Individuals with a history of cardiovascular disease are considered strong candidates. |
| Hypertension or Hyperlipidemia | These conditions are associated with increased cardiovascular risk and align with the profile of candidates for semaglutide. |
| Family History of Premature Cardiovascular Disease | A family history of premature cardiovascular disease indicates higher risk. |
| Diabetes or Prediabetes | While the SELECT trial focused on individuals without diabetes, those with prediabetes are relevant candidates due to elevated cardiovascular risk. |
| Severe or Longstanding Obesity (BMI ≥40 kg/m²) | Severe or longstanding obesity is a recognized criterion for considering semaglutide treatment. |
| Abdominal Adiposity | Central obesity is a significant risk factor for cardiovascular disease and aligns with the treatment goals of semaglutide. |
The benefits observed even in patients with relatively modest degrees of overweight is supported by the SELECT trial findings, which indicate that semaglutide can provide cardiovascular benefits across a range of BMI categories.
In the SELECT trial, discontinuation rates due to adverse events were higher with semaglutide compared to placebo. This is an important consideration when prescribing semaglutide.
Gastrointestinal side effects like nausea, vomiting, and diarrhea occurred more frequently with semaglutide. However, these symptoms generally improved over time in most patients.
Cases of severe hypoglycemia were rare in SELECT, but remain a potential risk to monitor, especially in diabetic populations.
Diabetic retinopathy complications were uncommon in both groups. However, retinopathy is a consideration with semaglutide use in diabetic patients.
The SELECT trial demonstrated significant cardiovascular benefits with semaglutide in people with obesity. However, a careful assessment of safety and individual factors is important when determining if semaglutide is an appropriate treatment option. Healthcare providers should consider both the benefits and potential risks on an individual patient basis.
In 2021, the FDA officially approved semaglutide 2.4 mg for chronic weight management in individuals with overweight or obesity. An FDA advisory committee had previously voted overwhelmingly to recommend this approval, concluding that the evidence was persuasive for significant weight loss efficacy along with cardiovascular risk reduction.
On the heels of SELECT, numerous ongoing trials are further evaluating semaglutide. Areas under investigation include:
SELECT provides a robust foundation supporting first-line use of semaglutide for cardiovascular risk mitigation in clinical obesity care. However, additional research will refine these applications.
Updated treatment guidelines are likely to position GLP-1 receptor agonists like semaglutide as preferred anti-obesity agents for patients with heightened cardiovascular risk. This paradigm shift promises to improve the historically dismal cardiovascular prognosis in obesity.
Obesity is a cardiovascular disease in its own right. Landmark SELECT trial results indicate semaglutide is highly effective at reducing the heightened cardiovascular event rate associated with excess weight.
Beyond significant weight reduction, semaglutide demonstrates multifactorial cardiovascular protection – decreasing the risk of heart attack, stroke, heart failure, hospitalization, and cardiovascular death. Benefits extend to those with and without established heart disease.
While long-term outcomes data remains limited, the favorable safety profile observed makes semaglutide an attractive option to mitigate cardiovascular risk in appropriately selected patients with overweight or obesity. This novel therapeutic approach could substantially lessen the burden of cardiovascular disease in a high-risk population.
Schedule your semaglutide consultation today at Dr. V Medical Aesthetics to discuss reducing cardiovascular risk through clinically meaningful weight loss
Dr. V Medical Aesthetics is ready to help you achieve your beauty goals. Contact us today to learn more about any of our services, and exactly what our team can do for you.
